PTC Therapeutics, Inc.

PTCT · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders7.3%

Institutions122.9%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$1.73B	$806.78M	$937.82M	$698.80M	$538.59M	$380.77M	$306.98M	$264.73M	$194.39M	$82.70M
The direct costs of producing what was sold — raw materials, manufacturing, direct labor.	–	–	–	–	–	–	$12.13M	$12.67M	$4.58M	–
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	$866.93M	-$302.57M	-$439.50M	-$447.41M	-$374.44M	-$431.77M	-$241.16M	-$115.69M	-$64.29M	-$132.06M
Operating income as a percentage of revenue.	50.1%	-37.5%	-46.9%	-64.0%	-69.5%	-113.4%	-78.6%	-43.7%	-33.1%	-159.7%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	$682.64M	-$363.30M	-$626.60M	-$559.02M	-$523.90M	-$438.16M	-$251.58M	-$128.08M	-$79.00M	-$142.11M
Net income divided by the number of shares outstanding — profit attributable to each share.	$8.58	$-4.73	$-8.37	$-7.79	$-7.43	$-6.64	$-4.00	$-2.00	$-2.00	$-4.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$7.78	$-4.73	$-8.37	$-7.79	$-7.43	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$984.65M	$779.71M	$594.00M	$279.83M	$189.72M	$208.81M	$288.03M	$169.50M	$111.79M	$58.32M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$2.90B	$1.71B	$1.90B	$1.71B	$1.94B	$2.21B	$1.62B	$1.12B	$391.65M	$269.35M
All of the company's interest-bearing borrowings, short and long term combined.	$286.63M	$285.41M	$284.21M	$571.72M	$431.43M	$309.14M	$313.86M	$153.01M	$144.97M	$98.22M
Everything the company owes — debt, unpaid bills, and other obligations.	$3.10B	$2.80B	$2.71B	$2.05B	$1.94B	$1.73B	$1.03B	$768.50M	$235.22M	$149.76M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	-$205.31M	-$1.10B	-$818.55M	-$347.09M	$1.44M	$481.98M	$594.33M	$350.73M	$156.44M	$119.58M

Cash Flow Statement

	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	$711.20M	-$107.69M	-$158.42M	-$356.65M	-$251.33M	-$194.07M	-$98.64M	-$27.64M	-$10.06M	-$103.57M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$8.86M	$6.50M	$28.44M	$32.02M	$28.21M	$17.84M	$13.76M	$7.10M	$3.10M	$1.78M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	$702.34M	-$114.19M	-$186.86M	-$388.67M	-$279.55M	-$211.91M	-$112.40M	-$34.74M	-$13.16M	-$105.34M

	You	Peer avg
Revenue Growth	+101.5%	+126.8%
ROE	–	-245.9%

PTC Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison